Detalles de la búsqueda
1.
Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
Oncologist
; 26(1): 49-55, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33044765
2.
Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018.
Oncologist
; 26(6): 514-522, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33655682
3.
Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy.
Oncologist
; 25(3): e398-e404, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162817
4.
Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study.
J Am Acad Dermatol
; 82(3): 743-746, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31349048
5.
Trends in the use of postprostatectomy therapies for patients with prostate cancer: a surveillance, epidemiology, and end results Medicare analysis.
Cancer
; 119(18): 3295-301, 2013 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23842985
6.
Racial differences in time from prostate cancer diagnosis to treatment initiation: a population-based study.
Cancer
; 119(13): 2486-93, 2013 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23716470
7.
Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control.
Cancer Med
; 8(11): 4986-4999, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31286682
8.
Cancer screening rates in individuals with different life expectancies.
JAMA Intern Med
; 174(10): 1558-65, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25133746
Resultados
1 -
8
de 8
1
Próxima >
>>